A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?
A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.
Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.
Despite government rhetoric, the US biosimilar market has failed to live up to expectations so far.
A cooling of the M&A climate allows Asia-based groups to come to the fore.